London-based GSK has introduced two cancer medicines Jemperli for certain advanced endometrial cancers and Zejula for advanced ovarian cancer, marking its formal entry into India’s oncology market. These cancers are increasingly common among Indian women, and many patients are diagnosed at later stages where treatment choices are limited.
Endometrial and ovarian cancers are among the most common cancers in Indian women, with cases projected to rise sharply by 2045. Nearly one-fourth of endometrial cancer patients in India present with advanced disease, where treatment options remain limited.
Jemperli is the first PD‑1 immunotherapy approved in India for specific types of advanced endometrial cancer, supported by clinical data showing meaningful response rates.
Zejula is the only once‑daily oral PARP inhibitor in India approved as a first‑line maintenance therapy for advanced ovarian cancer, regardless of biomarker status, with trials showing longer remission and slower disease progression.
Both therapies have global approvals across more than 40 countries, including the U.S., UK, and EU. In India, GSK is also involved in ongoing clinical trials to expand indications of Jemperli to other cancers, including non-small cell lung and colorectal cancer.
With these launches, GSK strengthens its specialty medicines portfolio in India, aiming to reshape cancer treatment pathways and offer patients targeted, evidence-backed options.
GSK has a long history in India and is currently focused on developing and marketing vaccines and prescription medicines for infectious diseases, respiratory issues, oncology, and immunology. operating for nearly a century in India with headquarters in Mumbai and manufacturing in Nashik, known for its strong vaccine portfolio and prescription drugs like Crocin and Sensodyne. India was the company’s largest market for Horlicks, a malted beverage for kids, but that business was sold to Unilever for $3.8 billion in 2020.
